Hikma Pharmaceuticals USA recently announced that it will invest $1 billion by 2030 to further expand U.S. manufacturing and R&D. London-based Hikma has already invested more than $4 billion over the past 15 years in expanding its U.S. presence, which was first established in 1991. The new “America Leans on Hikma” phase, announced June 28,…
Sandoz breaks ground on biosimilar plant in Slovenia
Sandoz announced that it began construction on a new, state-of-the-art biosimilars production center in Brnik, Slovenia. The $440 million project enables sterile product manufacturing in the region. It brings the company’s total planned and ongoing investment in Slovenia to more than $1.1 billion by 2029. Sandoz already has ongoing investments there, including a new biosimilar…
Nymi, Caliber partner on passwordless authentication for pharma manufacturing
Nymi today announced a strategic partnership with Caliber Technologies to accelerate digital transformation in pharmaceutical manufacturing. The partnership aims to enable passwordless authentication on the shop floor. This reduces manual logins and streamlines electronic signatures. Nymi offers the Band biometric, wearable device that authenticates users via fingerprint and facilitates a secure, continuous identity across applications,…
Building a resilient pharma supply chain
The pharmaceutical supply chain ensures medications reach patients safely and on time. About 75% of pharma executives say supply chain disruptions threaten patient health. The industry faces particular concern now: according to the Global Supply Chain Pressure Index (GSCPI), global supply chains witnessed major issues during the COVID-19 pandemic and ongoing geopolitical tensions. Here are…
Pharma ingredient manufacturer Antheia raises $56M Series C
Pharmaceutical ingredient manufacturer Antheia announced today that it raised $56 million in Series C financing. The Menlo Park, California-based company aims to deliver ingredients to transform essential medicine supply chains. It plans to use the financing to expand the commercialization of its first product, Thebaine. The company also plans to launch additional products from its…
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
ICU Medical and Otsuka Pharmaceutical Factory (OPF) announced the formation of a new joint venture to strengthen supply chain resiliency. In this joint venture, the companies say they formed Otsuka ICU Medical LLC. It aims to strengthen IV solutions supply chains and drive innovation in the North American market. The need for a more resilient…
Amgen to spend $900M to expand U.S. biopharma manufacturing
Amgen announced that it plans to invest $900 million to expand its pharmaceutical manufacturing facility in Ohio. The expansion brings the total number of jobs created to 750. Amgen’s total investment in central Ohio now eclipses $1.4 billion. “Amgen has been a leading U.S.-based manufacturer of biologic medicines since 1988. Today’s investment reinforces our ongoing…
Roche to invest $50B in U.S. over next five years
Roche announced plans to invest $50 billion in the U.S. over the next five years to boost manufacturing and R&D. Basel, Switzerland-based Roche says the investments strengthen its U.S. footprint and should create more than 12,000 new jobs. That includes nearly 6,500 construction jobs, plus 1,000 jobs at new and expanded facilities. As part of…
Thermo Fisher to invest $2B on U.S. manufacturing
Thermo Fisher Scientific announced today that it plans to invest an additional $2 billion in the U.S. over the next four years. The company said its investment should strengthen American innovation, manufacturing and economic competitiveness in the life sciences sector. It also comes as a number of companies consider investing in U.S. infrastructure amid potential…
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
Fujifilm Diosynth Biotechnologies, a major contract development and manufacturing organization (CDMO), has entered into a 10-year manufacturing supply agreement with Regeneron Pharmaceuticals, valued at over $3 billion. The deal has the Fujifilm subsidiary providing U.S.-based manufacturing for Regeneron, with planned expansions at Fujifilm’s large-scale biopharmaceutical manufacturing facility in Holly Springs, North Carolina. The Holly Springs…